IL17A and psoriasis: The current clinical treatment of psoriasis completely involves topical drugs, including vitamin D3 analogues, topical corticosteroids, calcineurin inhibitors, keratolytics, and biologics that inhibit TNF-α, IL-12, IL-13, IL-17, and IL-23 [31].